Phase 1
Regeneron and its longtime development partner Sanofi are keeping their proverbial fingers crossed that their profitable collaboration will yield yet another approved treatment this year.
At the World Medical Innovation Forum, panelists observed that AI can be used to scour old clinical trial data for new applications and possibly take over part of clinical trials in “virtual” models.
ADC Therapeutics has pulled the plug on its Phase I drug candidate that targets solid tumors with HER2 expression.
The biopharma industry is starting to leverage mobile apps and other digital technologies to improve access to clinical trials. Novartis launched FocalView, an app for ophthalmic patients involved in eye-related clinical trials.
Prothena Corporation announced it had shuttered its NEOD001 program for AL amyloidosis after the failure of its Phase IIb PRONTO study and Phase III VITAL study. Shares dropped 60 percent in premarket trading at the news.
Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
With growing concerns about the rise of drug resistant bacteria, multiple companies are developing new forms of antimicrobials to take on serious health concerns.
The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.
It seems inevitable that as marijuana becomes more broadly legal in the U.S., that the biopharma industry and larger corporations will take an interest.
Fueled by positive Phase I and Phase I/II results from an open-label extension (OLE) study of RNAi therapeutic givosiran, as well as an ongoing Phase III trial, Cambridge, Mass.-based Alnylam said it is eying a possible New Drug Application by the end of the year.
PRESS RELEASES